Targeted Oncology - Immunotherapy, Biomarkers, and Cancer …
Nivolumab demonstrated superior efficacy in LA-HNSCC, whereas the combination of durvalumab and cetuximab showed limited success. Abenacianine received fast track designation for lung cancer surgery, the combination of amivantamab and Lazertinib showed OS improvement in NSCLC, and sunvozertinib has been granted priority review status for NSCLC.
5-Year Update Sustains Nivolumab/Chemo Efficacy in Frontline …
15 小时之前 · The first-line combination of nivolumab (Opdivo) and chemotherapy continued to show deep responses and an overall survival (OS) benefit vs chemotherapy alone in patients with advanced gastric cancer, gastroesophageal junction (GEJ) cancer, and esophageal adenocarcinoma (EAC), according to 5-year follow-up data from the phase 3 CheckMate 649 …
Evorpacept Plus TRP Betters Survival in HER2+ Gastric/GEJ Cancer
14 小时之前 · The CD47 myeloid checkpoint inhibitor evorpacept (ALX148), in combination with trastuzumab (Herceptin), paclitaxel, and ramucirumab (Cyramza; TRP), resulted in favorable survival outcomes and responses compared to TRP alone in patients with HER2-positive gastric or gastroesophageal junction (GEJ) cancer.
Daratumumab With Lenalidomide Enhances Outcomes in NDMM
1 天前 · Ashraf Z. Badros, MB, ChB, professor of medicine, director of the Multiple Myeloma Service, and vice chair of the Clinical Research Committee for the Program in Oncology at the University of Maryland School of Medicine in Baltimore, discusses the results of the phase 3 AURIGA trial (NCT03901963) which evaluated daratumumab (Darzalex) and lenalidomide vs …
Patient Considerations for Front-line Systemic Immunotherapies in …
1 天前 · James J. Harding, MD, discusses how the initial findings from CheckMate 9DW inform the role of nivolumab plus ipilimumab (NIVO + IPI) in the first-line (1L) treatment landscape for unresectable hepatocellular carcinoma (uHCC), considering factors such as efficacy, safety, and patient characteristics (eg, age) when selecting between first-line systemic immunotherapy …
Breast Cancer | Oncology News & Insights | Targeted Oncology
January 13th 2025. During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed how the outcomes of the DESTINY-Breast03 and other trials impact treatment of metastatic HER2-positive breast cancer in the second article of a 2-part series.
ADCs Change the Game for Cancer Treatment - Targeted Oncology
2024年5月29日 · Loncastuximab Tesirine. The CD19-directed loncastuximab tesirine-lpyl (Zynlonta) gained an FDA orphan drug designation in 2017 7 and was granted accelerated approval in April 2021 for patients with large B-cell lymphoma. The approval was supported by the LOTIS-2 study (NCT03589469), which enrolled 145 patients who were relapsed/refractory to …
Treatment Resources - Targeted Oncology
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
GI CANCERS - Targeted Oncology
January 17th 2025. LOAd703, an oncolytic adenovirus with transgenes for 4-1BBL and TMZ-CD40L, has received FDA fast track designation for pancreatic cancer treatment.
Prostate Cancer - Targeted Oncology
During an in-person Community Case Forum event in Miami, Florida, Mike Cusnir, MD, discussed the ARANOTE study outcomes presented at ESMO 2024 and how they fit into the treatment paradigm for patients with metastatic hormone-sensitive prostate cancer. Data from the phase 3 CAPItello-281 trial showed ...